AU2019257722B2 - SLC26A3 inhibitors and use thereof - Google Patents

SLC26A3 inhibitors and use thereof Download PDF

Info

Publication number
AU2019257722B2
AU2019257722B2 AU2019257722A AU2019257722A AU2019257722B2 AU 2019257722 B2 AU2019257722 B2 AU 2019257722B2 AU 2019257722 A AU2019257722 A AU 2019257722A AU 2019257722 A AU2019257722 A AU 2019257722A AU 2019257722 B2 AU2019257722 B2 AU 2019257722B2
Authority
AU
Australia
Prior art keywords
compound
slc26a3
constipation
oxalate
dra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019257722A
Other languages
English (en)
Other versions
AU2019257722A1 (en
Inventor
Onur CIL
Peter M. HAGGIE
Alan S. Verkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California San Diego UCSD filed Critical University of California
Publication of AU2019257722A1 publication Critical patent/AU2019257722A1/en
Application granted granted Critical
Publication of AU2019257722B2 publication Critical patent/AU2019257722B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
AU2019257722A 2018-04-25 2019-04-25 SLC26A3 inhibitors and use thereof Active AU2019257722B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662574P 2018-04-25 2018-04-25
US62/662,574 2018-04-25
PCT/US2019/029219 WO2019210103A2 (en) 2018-04-25 2019-04-25 Slc26a3 inhibitors and use thereof

Publications (2)

Publication Number Publication Date
AU2019257722A1 AU2019257722A1 (en) 2020-11-19
AU2019257722B2 true AU2019257722B2 (en) 2025-04-03

Family

ID=67439317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019257722A Active AU2019257722B2 (en) 2018-04-25 2019-04-25 SLC26A3 inhibitors and use thereof

Country Status (6)

Country Link
US (2) US11591304B2 (https=)
EP (1) EP3784229A2 (https=)
JP (1) JP7442824B2 (https=)
AU (1) AU2019257722B2 (https=)
CA (1) CA3098293A1 (https=)
WO (1) WO2019210103A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019005196A1 (de) * 2019-07-25 2021-01-28 Forschungszentrum Jülich GmbH Verfahren zur Herstellung eines Cumarin-caged Forskolinderivats, Forskolinderivat und Verwendung des Forskolinderivats
WO2023009836A1 (en) 2021-07-30 2023-02-02 The Regents Of The University Of California Slc26a3 inhibitors and use thereof
WO2023081967A1 (en) * 2021-11-10 2023-05-19 The University Of Western Australia Compounds and uses therefor
CN117298113A (zh) * 2023-10-31 2023-12-29 东南大学 替那帕诺及其脂质体靶向m2巨噬细胞在抗肿瘤药中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056914A1 (en) * 2008-11-12 2010-05-20 Microbiotix, Inc. Bacterial helicase inhibitor compounds and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101362722B (zh) * 2008-09-27 2011-04-27 山东大学 N-取代苯基-2-(1-芳基-1h-咪唑-2-巯基)乙酰胺类衍生物及其制备方法与应用
EP3419612B1 (en) 2016-02-26 2024-11-06 The Regents of the University of California Heterocyclic small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056914A1 (en) * 2008-11-12 2010-05-20 Microbiotix, Inc. Bacterial helicase inhibitor compounds and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "qHTS for Inhibitors of Glutaminase (GLS)", PubChem, 22 May 2012, XP055624028, Retrieved from the Internet https://pubchem.ncbi.nlm.nih.gov/bioassay/624170 https://pubchem.ncbi.nlm.nih.gov/compound/1799978 *
ANONYMOUS: Internet https://pubchem.ncbi.nlm.nih.gov/bioassay/1949 https://pubchem.ncbi.nlm.nih.gov/compound/1748663, https://pubchem.ncbi.nlm.nih.gov/compound/907529, https://pubchem.ncbi.nlm.nih.gov/compound/1294768 *
ANONYMOUS: PubChem, 17 Apr 2017, retrieve from the internet https://pubchem.ncbi.nlm.nih.gov/bioassay/1259310 https://pubchem.ncbi.nlm.nih.gov/compound/1748060 *
ANONYMOUS: PubChem, 22 Jun 2011, retrieve from the internet https://pubchem.ncbi.nlm.nih.gov/bioassay/504834 https://pubchem.ncbi.nlm.nih.gov/compound/1319039 *
ANONYMOUS: XP055623959, Retrieved from the Internet https://pubchem.ncbi.nlm.nih.gov/bioassay/540297 https://pubchem.ncbi.nlm.nih.gov/compound/1295810 *
BING LI ET AL: , JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 24, 11 December 2012 (2012-12-11), US, pages 10896 - 10908, XP055622205, ISSN: 0022-2623, DOI: 10.1021/jm300922h *

Also Published As

Publication number Publication date
US11591304B2 (en) 2023-02-28
WO2019210103A3 (en) 2020-01-16
CA3098293A1 (en) 2019-10-31
WO2019210103A2 (en) 2019-10-31
AU2019257722A1 (en) 2020-11-19
US20230339878A1 (en) 2023-10-26
JP2021522255A (ja) 2021-08-30
EP3784229A2 (en) 2021-03-03
US20210363123A1 (en) 2021-11-25
US12187694B2 (en) 2025-01-07
JP7442824B2 (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
US12187694B2 (en) SLC26A3 inhibitors and use thereof
CA2793856C (en) Tetrahydrobenzothiophene compound
CA2965741C (en) Pharmaceutical compound
AU2007282465B2 (en) Sulfonamide compound or salt thereof
WO2008062740A1 (fr) Composé azoté à anneaux fusionnés et son utilisation
WO2019226991A1 (en) Androgen receptor modulators and methods for their use
US9944605B2 (en) Farnesoid X receptor antagonists
WO2007142323A1 (ja) 側鎖にスピロ環構造を有する新規インダゾール誘導体
CA2966303A1 (en) Substituted pyridines as bromodomain inhibitors
JP2018509397A (ja) 胃排出の減少方法及び組成物
JP2008189549A (ja) カルボン酸誘導体またはその塩
CN110240587A (zh) 一类芳基二氟苄基醚类化合物、制备方法及用途
US20080194563A1 (en) Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases
AU2001261471A1 (en) Phosphate transport inhibitors
CN118103357A (zh) Fabp4/5抑制剂、使用方法和制备方法
CN108699040B (zh) Cftr调节剂及其使用方法
WO2019222134A1 (en) Coup-tfii receptor inhibitors and methods using same
WO2006080287A1 (ja) ２－アゾリルイミノ－１，３－チアジン誘導体
JP2019501137A (ja) ４−オキソ−４，５−ジヒドロチアゾール誘導体、その調製方法及び使用
JPWO2002042297A1 (ja) ピペリジン化合物およびその医薬用途
WO2006080284A1 (ja) ２－置換イミノ－１，３－オキサジン誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)